3-Octadecyl-4-oxo-2-thioxothiazolidin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-Octadecyl-4-oxo-2-thioxothiazolidin
• 英文别名: 3-Octadecyl-2-sulfanylidene-1,3-thiazolidin-4-one
• 化学式: C₂₁H₃₉NOS₂
• 分子量: 385.679
• InChiKey: CSOXJLLBMDDPJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.7
• 重原子数：
  25
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  77.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  四甲基氯化铵 、 3-Octadecyl-4-oxo-2-thioxothiazolidin 、 4-<2-(2-anilinovinyl)benzothiazol-2-io>butansulfonat 在 三乙胺 作用下， 以81%的产率得到Tetramethylammonium-4-<2,3-dihydro-2-<2-(3-octadecyl-4-oxo-2-thioxothiazolidin-5-yliden)ethyliden>benzothiazol-3-yl>butansulfonat
  参考文献：
  名称：

  Neue Dimethinmerocyanin-Farbstoffe mit der（Sulfobutyl）苯并噻唑-Gruppe als Donor-Teilchromophor und deren

  摘要：

  （磺丁基）苯并噻唑基为发色团的供体部分的新型二甲亚甲基花青染料及其在水溶液中的聚集趋势

  DOI：

  10.1002/hlca.19890720214

文献信息

• [EN] PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN DERIVE DE BENZODIAZEPINE ET UN INHIBITEUR DE LA PROTEINE DE FUSION DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005089771A1

  公开（公告）日：2005-09-29

  A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.

  一种包含药用可接受载体或稀释剂以及：(a) RSV融合蛋白抑制剂；和(b) 能够抑制RSV复制的苯二氮䓬类衍生物的药物组合物被发现对RSV具有很高的活性。
• 3D-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
  申请人：The Regents of the University of California

  公开号：US11243215B2

  公开（公告）日：2022-02-08

  In various embodiments methods are provided for identifying and/or quantifying one or more antigens of interest (biomarkers) on the surface of cell- or tissue-specific exosomes. In an illustrative embodiments the methods comprise: i) incubating a population of exosomes with one or more tissue-specific antibodies that bind an antigen specific to a tissue or cell type of interest that produces exosomes, where the tissue specific antibodies are attached to acceptor bead or magnetic beads so the antibodies bind exosomes displaying the antigen; ii) obtaining a purified population of exosomes bound by the tissue specific antibodies with and/or without photocleavable linker based technology; iii) incubating a test subset of the isolated tissue-specific exosomes with acceptor beads attached to test antibodies that bind an antigen of interest thereby binding exosomes that display the antigen of interest and a control subset with negative control acceptor beads; v) incubating the test subset of isolated exosomes and the control subset of exosomes with a donor-bearing antibody that binds an exosome specific antigen; and vi) detecting a signal produced upon illumination of the control subset and/or the test; and vii) detecting the antigen(s) of interest.

  在各种实施例中，提供了用于识别和/或定量细胞或组织特异性外泌体表面上的一个或多个感兴趣的抗原（生物标志物）的方法。在一个说明性实施例中，该方法包括：i）将外泌体群体与一个或多个组织特异性抗体孵育，这些抗体与特定于产生外泌体的感兴趣组织或细胞类型的抗原结合，其中这些组织特异性抗体附着在受体珠或磁珠上，使抗体结合显示抗原的外泌体；ii）获得由组织特异性抗体结合的外泌体的纯化群体，有时使用光解链技术；iii）将分离的组织特异性外泌体的测试子群体与附着有结合感兴趣抗原的测试抗体的受体珠孵育，从而结合显示感兴趣抗原的外泌体，以及一个带有阴性对照受体珠的对照子群体；v）将分离的外泌体的测试子群体和对照子群体与结合外泌体特异性抗原的供体抗体孵育；vi）在照射对照子群体和/或测试子群体时检测产生的信号；以及vii）检测感兴趣的抗原。
• Guanidinoglycoside-mediated liposome-based delivery of therapeutics
  申请人：The Regents of the University of California

  公开号：US20180086782A1

  公开（公告）日：2018-03-29

  This disclosure relates to the incorporation of amphiphilic guanidinylated aminoglycosides (e.g., neomycin) into liposomal assemblies, which contain entrapped therapeutics. The lysosome is responsible for enzymatically breaking down and recycling large biomolecules and aged organelles. While malfunctioned lysosomal enzymes have been established in Lysosomal Storage Disorders (LSDs), recent reports have suggested that defects in lysosomal enzymes (e.g., glucocerebrosidase) are also linked to other chronic ailments, including neurological disorders such as Parkinson's Disease and related disorders.

  本公开涉及将两性亲和性胍基化氨基糖苷（例如新霉素）纳入含有封闭治疗剂的脂质体聚集体中。溶酶体负责酶解和回收大分子生物分子和老化的细胞器。虽然已经确定溶酶体酶在溶酶体贮积病（LSDs）中存在故障，但最近的报告表明，溶酶体酶（例如葡萄糖鞘脂酶）的缺陷也与其他慢性疾病有关，包括神经疾病如帕金森病及相关疾病。
• Hydrophobically-modified protein compositions and methods
  申请人：Pepinsky Blake R.

  公开号：US20050119181A1

  公开（公告）日：2005-06-02

  Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.

  描述了一种水疏性修饰蛋白质及其制备方法。将一种疏水基团附加到蛋白质的表面氨基酸残基上。该疏水基团可以是脂质或肽。或者，可以通过各种化学反应使蛋白质衍生出一个疏水结构。优选的蛋白质是哺乳动物来源的，并从Sonic，Indian和Desert hedgehog组中选择。该疏水基团可用作方便的系链，可附着细胞膜、脂质体或微胶束等载体。
• Severe acute respiratory syndrome coronavirus
  申请人：Rappuoli Rino

  公开号：US20060257852A1

  公开（公告）日：2006-11-16

  An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.

  2003年，在中国香港和世界各地越来越多的国家中，爆发了一种名为严重急性呼吸综合症（SARS）的致命呼吸道病毒。本发明涉及来自SARS冠状病毒的核酸和蛋白质。这些核酸和蛋白质可以用于制备和制造疫苗配方、诊断试剂盒等。本发明还提供了通过给予小分子抗病毒化合物治疗SARS的方法，以及识别用于治疗SARS的有效小分子的方法。